The combined use of perfluorohexyloctane (F6H8) and silicone oil as an intraocular tamponade in the treatment of severe retinal detachment

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 6, 2006, Pages 709-716

  Rizzo, Stanislao ^a,b   Genovesi Ebert, Federica ^a   Belting, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NONE   (Italy)

Author keywords

Complicated retinal detachment; Double filling; Perfluorohexyloctane (FGH8); Silicone oil

Indexed keywords

PERFLUOROHEXYLOCTANE; SILICONE OIL;

ADULT; AGED; ARTICLE; CATARACTOGENESIS; CHOROID DETACHMENT; CILIARY DISK; CONTROLLED STUDY; DEVICE REMOVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEMBRANE FORMATION; OUTCOMES RESEARCH; PENETRATING TRAUMA; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINA INJURY; RETINA TEAR; TREATMENT FAILURE; VISUAL SYSTEM EXAMINATION; VITRECTOMY; VITREORETINOPATHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DRAINAGE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROCARBONS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETINA; RETINAL DETACHMENT; SILICONE OILS; VISCOSITY; VISUAL ACUITY; VITRECTOMY;

EID: 33745228072     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-006-0317-3     Document Type: Article

References (27)

1. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, Aylward GW (2001) Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind controlled clinical trial. Ophthalmology 108:1179-1183
2. Chang S, Zimmermann NJ, Iwamoto T, Ortiz R, Faris D (1987) Experimental vitreous replacement with perfluorotributylamine. Am J Ophthalmol 103:29-37
3. Chang S, Sparrow JR, Iwamoto T, Gershbein A, Ross R, Ortiz R (1991) Experimental studies of tolerance to intravitreal perfluoro-n-octane liquid. Retina 11:367-374
4. Cox MS, Trese MT, Murphy PL (1986) Silicone oil for advanced proliferative vitreoretinopathy. Ophthalmol 93:646-650
5. De Molfetta V, Bottoni F, Arpa P, Vinciguerra P, Zenoni S (1992) The effect of simultaneous internal tamponade on fluid compartimentalization and its relationship to cell proliferation. Retina 12:S40-S45
6. Eckart C, Nicolai U, Winter M, Knop E (1991) Experimental intraocular tolerance to liquid perfluorooctane and perfluoropolyether. Retina 11:375-384
7. Fleury J, Bonnet M (1992) Prognostic value of new retinal tears associated with the development of postoperative proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 230:459-462
8. Herbert E, Stappler T, Wetterqvist C, Williams R, Wong D (2004) Tamponade properties of double-filling with perfluorohexyloctane and silicone oil in a model eye chamber. Graefes Arch Clin Exp Ophthalmol 242:692-696
9. Hiscott P, Magee RM, Colthurst M, Lois N, Wong D (2001) Clinicopathological correlation of epiretinal membranes and posterior lens opacification following perfluorohexyloctane tamponade. Br J Ophthalmol 85:179-183
10. Jonas JB, Knorr HLJ, Rank RM, Budde WM (2001) Retinal detachment after removal of intraocular silicone oil tamponade. Br J Ophthalmol 85:1203-1207
11. Kirchhof B, Wong D, Van Meurs J, Hilgers RD, Macek M, Lois N, Schrage NF (2002) Use of perfluorohexyloctane as a long-term internal tamponade agent in complicated retinal detachment surgery. Am J Ophthalmol 133:95-101
12. Mandai M, Takanashi T, Ogura Y, Honda Y (1990) Proliferative vitreoretinopathy shows predilection for the inferior fundus. Graefes Arch Clin Exp Ophthalmol 228:335-337
13. Meinert H, Roy T (2000) Semifluorinated alkanes - a new class of compounds with outstanding properties for use in ophthalmology. Eur J Ophthalmol 10:189-197
14. Michels RG (1984) Surgery of retinal detachment with proliferative vitreoretinopathy. Retina 4:63-83
15. No authors listed (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121-125
16. Orzalesi N, Migliavacca L, Bottoni F, Miglior S (1998) Experimental short-term tolerance to perfluorodecalin in the rabbit eye: A histological study. Curr Eye Res 17:828-835
17. Peyman GA, Conway MD, Soike KF, Clark LC Jr (1991) Long-term vitreous replacement in the primates with intravitreal Vitreon or Vitreon plus silicone. Ophthalmic Surg 22:657-664
18. Peyman GA, Schulman JA, Sullivan B (1995) Perfluorocarbon liquids in ophthalmology. Surv Ophthalmol 39:375-395
19. Parel JM (1992) Olii di silicone: Proprietà fisicochimiche. In: Ryan SJ (ed) Retina, vol. 3 (Italian edition). Medical Books, Palermo, pp 271-289
20. Sparrow JR, Jayakumar A, Berrocal M, Ozmert E, Chang S (1992) Experimental studies of the combined use of vitreous substitutes of high and low specific gravity. Retina 12:134-140
21. Stefaniotou MI, Aspiotis MV, Kitsos GD, Kalogeropoulos CD, Asproudis IC, Psila KG (2002) Our experience with perfluorohexyloctane (F6H8) as a temporary endotamponade in vitreoretinal surgery. Eur J Ophthalmol 12:518-522
22. Tanji TM, Peyman GA, Mehta NJ, Millsap CM (1993) Perfluoroperhydrophenanthrene (Vitreon) as a short-term vitreous substitute after complex vitreoretinal surgery. Ophthalmic Surg 24:681-685
23. Velikay M, Wedrich A, Stolba U, Datlinger P, Li Y, Binder S (1993) Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin. Am J Ophthalmol 116:565-570
24. Velikay M, Stolba U, Wedrich A, Li Y, Datlinger P, Binder S (1995) The effect of chemical stability and purification of perfluorocarbon liquids in experimental extended-term vitreous substitution. Graefes Arch Clin Exp Ophthalmol 233:26-30
25. Wolf S, Schön V, Meier P, Wiedemann P (2003) Silicone oil-RMN3 mixture ("heavy silicone oil") as internal tamponade for complicated retinal detachment. Retina 23:335-342
26. Wong D, Lois N (2000) Perfluorocarbons and semifluorinated alkanes. Semin Ophthalmol 15:25-35
27. Zeana D, Becker J, Kuckelkorn R, Kirchhof B (1999) Perfluorohexyloctane as a long-term vitreous tamponade in the experimental animal. Experimental perfluorohexyloctane substitution. Int Ophthalmol 23:17-24